Assessment of Non-Invasive Testing in Major Liver-Related Outcomes

Launched by HRI-MAIL-NIT · May 15, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on studying a liver condition called Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its more severe form, Metabolic Dysfunction-Associated Steatohepatitis (MASH), particularly in patients who may also have issues related to alcohol consumption (MetALD). Researchers want to understand how well non-invasive tests, like MRI and Fibroscan, can help monitor these diseases over time. By collecting information about patients' health, the trial aims to find ways to better track the progression of liver disease and potentially reduce the need for more invasive procedures, like liver biopsies, in the future.

To join this study, participants should be adults aged 18 to 80 who have specific evidence of liver disease, such as significant liver stiffness. However, those with certain other liver conditions or recent serious health issues may not be eligible. If you participate, you can expect to undergo non-invasive tests and provide health information over time, helping researchers learn more about these liver diseases and improve future treatments. It's important to note that this trial is not yet recruiting participants, but it aims to shed light on a condition that is not well understood and could lead to better care for many people.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • -
• Inclusion Criteria:
• • 1. Adults, 18-80, male or female.
• • 2. Cohort A (MASH): Evidence of MASH (metabolic dysfunction-associated steatohepatitis) with fibrosis stage 3 or higher based on MRE stiffness of \>3.63 kPa or liver biopsy.
• • Cohort B (MetALD): Evidence of MetALD/ALD as defined by the AASLD nomenclature criteria and evidence of liver stiffness of 12 kPa or higher on VCTE.
• • 3. Willingness to participate in the study. Exclusion criteria
• • <!-- -->
• • 1. Involvement in the planning and/or conduct of the study (including sponsors, clinic staff, and vendors)
• • 2. Participation in another clinical study with intake of an investigational product during the last 60 days prior to Baseline
• • 3. Participation in a large multinational observational cohort (local registry and biobank are allowed) Target disease exclusions
• • 4. History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to baseline (For Cohort A only).
• • 5. MELD score ≥12, as determined at baseline, due to liver disease.
• 6. Evidence of current, chronic liver diseases at the time of baseline:
• • a. Primary biliary cholangitis b. Primary sclerosing cholangitis c. Chronic hepatitis B or D d. Hepatitis C, as defined by the presence of hepatitis C virus antibody (anti-HCV) with detected circulating ribonucleic acid (RNA) within two years prior to Screening, or during Screening Period.
• • e. HCV eradication by antiviral treatment less than three years prior to Screening.
• • f. History or evidence of current active autoimmune hepatitis g. History or evidence of Wilson's disease h. History or evidence of alpha-1-antitrypsin deficiency i. Evidence of genetic hemochromatosis (hereditary, primary) j. Evidence of drug-induced liver disease k. Known bile duct obstruction. l. Suspected or proven hepatocarcinoma, or metastatic tumor in the liver
• 7. Evidence of hepatic impairment or decompensation within 3 months prior to baseline, as defined by any of the following parameters:
• • a. History of ascites, or hepatic encephalopathy b. History of variceal bleeding c. Serum albumin \< 3.5 g/dL, except as explained by non-hepatic causes. d. International Normalized Ratio (INR) ≥ 1.3, except for participants under anticoagulant treatment.
• • o NOTE: INR may be repeated once to reassess eligibility e. Total bilirubin (TBL) ≥ 1.5 ULN
• • o NOTE: Patients with Gilbert's Syndrome are eligible with a total bilirubin above 1.5 × ULN if reticulocyte count is within normal limits (typically 0.5% to 2.5%), hemoglobin is within normal limits (typically 13.5 to 17.5 g/dL for men or 12.0 to 15.5 g/dL for women), and direct bilirubin is \<20% of total bilirubin f. Platelet count \< 110,000/mm3
• • 8. Prior history of medium or large varices
• • 9. Bariatric surgery of any kind within 2 years prior to the baseline visit Medical History and Concurrent Disease Exclusions Cardiovascular diseases
• 10. Any of the following diseases or procedures within 24 weeks prior to baseline:
• • 1. Myocardial infarction (MI)
• • 2. Cardiac revascularization surgery (coronary artery bypass graft / percutaneous transluminal coronary angioplasty (CABG / PTCA))
• • 3. Unstable angina
• • 4. Transient ischemic attack, stroke or cerebrovascular disease Hematological and oncological diseases
• • 11. Active malignancy with a complete remission date within 2 years prior to the baseline visit (except for treated basal cell carcinoma or treated squamous cell carcinoma of the skin or resected carcinoma of the cervix) Other exclusion conditions
• • 12. Immunocompromised participants such as participants that underwent organ transplantation or are diagnosed with human immunodeficiency virus (HIV) or participants with ongoing chemotherapy for stable malignant disease (such as a PD-1 inhibitor)
• • 13. Any other known serious disease (such as major infection, clinically significant gastrointestinal disorder, major autoimmune disease) or other disease which in the Investigator's opinion would exclude the participant from the study.
• • 14. Mental handicap, limited capacity of recognition, inability to follow the study procedures as evaluated by the Investigator, or any history of clinically important emotional and/or psychiatric illness.
• • 15. Use of non-permitted concomitant medication within 8 weeks prior to the initial baseline visit (A transient intake \< 4 weeks may be allowed after approval of the Medical Monitor)
• • 1. Vitamin E \>400 units per day. Participants on stable vitamin E therapy (same doses) for the last 12 weeks prior to baseline are eligible but the therapy should be maintained at stable dose throughout the study
• • 2. Pioglitazone \>15 mg per day. Participants on stable pioglitazone therapy (same doses) for the last 12 weeks prior to baseline are eligible but the therapy should be maintained at stable dose throughout the study
• • 3. GLP1-RA, SGLT2-I unless on stable doses for the last 12 weeks prior to baseline
• • 4. Amiodarone within 12 months of enrollment
• • 5. Methotrexate within 12 months of enrollment
• • 6. Chronic use (\> 2 consecutive weeks) of corticosteroids with a systemic effect at doses ≥ 5 mg/day of oral prednisone (or equivalent)
• • 7. Tamoxifen within 12 months of enrollment
• • 8. Estrogens at doses greater than those used for hormone replacement or contraception
• • 9. Anabolic steroids except testosterone replacement
• • 10. Valproic acid
• • 11. Any other medications known to affect liver function/steatosis at the Investigator's discretion (including vitamins, herbal and dietary supplements)
• 16. Contraindications to MRI, including:
• • 1. Participants with incompatible pacemakers, metallic cardiac valves, magnetic material such as surgical clips, implanted electronic infusion pumps or other conditions that would preclude proximity to a strong magnetic field
• • 2. History of extreme claustrophobia
• • 3. The participant cannot fit inside the magnetic resonance scanner cavity
• Exclusion Criteria:
• • -